58574-60-0

Upstream product

• 13552-47-1 3-(dimethylamino)-1-(p-tolyl)propan-1-one 
• 122-00-9 para-methylacetophenone 
• 5250-02-2 3-(dimethylamino)-4'-methyl propiophenone hydrochloride 

Downstream Products

• 1346460-46-5 N,N-dimethyl-3-(4-methylphenyl)-3-morpholino-propylamine hydrochloride 
• 917351-49-6 3-dimethylamino-1-(4-methylphenyl)propanamine 
• 1026673-39-1 C₁₄H₂₂N₂O 
• 88384-32-1 Carbonic acid 3-dimethylamino-1-p-tolyl-propyl ester phenyl ester; hydrochloride 

Relevant academic research and scientific papers

ARALKYL DIAMINE DERIVATIVES AND USES THEREOF AS ANTIDEPRESSANT

Aralkyl diamine derivative of the following formula, pharmaceutically acceptable salts or uses thereof as antidepressants. The derivatives have triplex inhibiting activities of the reuptake of 5-HT, dopamine and noradrenalin, which can be administered to the patients in need of such treatment in the form of compositions orally or injectedly et al.

Design, parallel synthesis and SAR of novel urotensin II receptor agonists

A 30-membered library of amides based on the potent urotensin II (UII) receptor agonist FL104, has been synthesized from ten different carboxylic acids and three amines. A synthetic protocol producing the amides in 47-98% yield has been developed in which

UII-MODULATING COMPOUNDS AND THEIR USE

Disclosed herein are novel aromatic-containing compounds and methods for using various aromatic-containing compounds for treatment and prevention of diseases and disorders related to the Urotensin II receptor.

Duloxetine (Cymbalta), a dual inhibitor of serotonin and norepinephrine reuptake.

A series of naphthalenyloxy-arylpropylamines have been prepared and are demonstrated to be inhibitors of both serotonin and norepinephrine reuptake. One member of this series, duloxetine (Cymbalta) has proven to be effective in clinical trials for the treatment of depression.